The U.S. Senate on Friday voted 62-28 for a bill that would establish a one-year pilot program through which pharmacists and wholesalers in the United States could reimport prescription drugs from Canada, where the medications often sell for a fraction of the U.S. price, the Los Angeles Times reports. Many anti-HIV medications, for example, can be bought in Canada for less than half of the price charged in the United States. However, the measure, attached as an amendment to the Medicare reform bill, includes a provision that allows Health and Human Services secretary Tommy Thompson to certify that the medications to be reimported are safe and would save consumers money, which could be used by the Bush administration to prevent the program from ever launching. The Food and Drug Administration and the Pharmaceutical Research and Manufacturers of America oppose the amendment due to safety concerns. Mark McClellan, director of the FDA, said his agency would not be able to guarantee the safety or efficacy of drugs reimported from Canada and worries that the Senate proposal would "create a wide inlet for counterfeit drugs and other dangerous products." The Medicare reform bill currently before the U.S. House does not include a drug reimportation measure, but Rep. Gil Gutknecht (R-Minn.) said he plans to introduce legislation that would allow medications to be reimported from several countries, with or without HHS approval.
Search
AI Powered
Human content,
AI powered search.
Latest Stories
Stay up to date with the latest in LGBTQ+ news with The Advocate’s email newsletter, in your inbox five days a week.
@ 2026 Equal Entertainment LLC.
All rights reserved
All rights reserved
By continuing to use our site, you agree to our Privacy Policy and Terms of Use.
The Latest
Support Independent Journalism
LGBTQ+ stories deserve to betold.
Your membership powers The Advocate's original reporting—stories that inform, protect, and celebrate our community.
Become a Member
FOR AS LITTLE AS $5. CANCEL ANYTIME.
More For You
Most Popular
@ 2026 Equal Entertainment LLC. All Rights reserved














